Researchers at Queen's University have developed a new way of performing lab tests that could improve the way doctors manage prostate cancer treatment. It will allow them to identify with unprecedented accuracy losses of a gene called PTEN that is associated with an aggressive group of prostate cancers. The improved Fluorescence In-Situ Hybridization (FISH) platform uses DNA probes to analyze the three-dimensional space cancer cells occupy in routine clinical microscopic analysis of tissue sections of tumors... 
More...
More...